comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 13:46:15 - browse：38

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： #NeedHerScience: shining a light on gender disparities in medicine

WSS

New guidelines on severe brain injury complicate already difficult decisions

The strategy behind pharma's lawsuits over drug pricing reform

Colonoscopy at 40? Study finds a possible benefit

Do masks work? RCTs can't tell us

The science behind Janet Jackson's pregnancy at 49

With FDA staff opposed to Sarepta therapy, top official intervened

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

With FDA staff opposed to Sarepta therapy, top official intervened

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why we need to separate burnout from moral injury in health care

23andMe had bad news about my health. I wish a person had delivered it

Digital health: a case of mistaken identity

Bright Health sells Medicare Advantage business to Molina

3 hurdles to bringing medical devices to the U.S. market

Duchenne breakthrough therapy leaves behind pioneering families

For longer

hotspot

ASCO eve: Let’s set the table for this year's meeting

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Weight bias in eating disorder treatment complicated by new weight loss drugs

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Making the case for fair compensation in clinical trials

Listen: A conversation with researcher Kevin Esvelt on biosecurity

explore

focus

Wikipedia

knowledge